In 2023, the number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in the US was recorded at 98 cases. From the forecasted data, a steady decline in cases is observed from 2024 to 2028, decreasing annually from 93 to 80 cases. Year-on-year percentage decreases are evident, with an average annual decline of approximately 4.94% over this five-year span. The Compound Annual Growth Rate (CAGR) suggests a continued decline at a moderate pace.
Future trends to watch for include potential impacts of new treatment protocols and public health interventions aimed at reducing TB transmission rates. Monitoring changes in drug resistance patterns is essential to adapt strategies effectively.
